LGALS1 and Parkinson disease: As pre-clinical models reveal that N-glycan branching also directly suppresses neuronal death [39] and its ligand (galectin-1) inhibits microglial-dependent neurodegeneration [36], GlcNAc therapy should additionally be considered for investigation in neurodegenerative disorders with microglia-associated inflammation, such as Alzheimer’s and Parkinson’s diseases.